3741 - 3750 of 8112 Results
Title
Year
- Toward e‐Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales2020OPENTitle: Toward e‐Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating ScalesJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 8Issue #: 2Start Page: 208End Page: 214Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13135Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13135Citation Count: 7
- Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson’s Disease2020OPENTitle: Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson’s DiseaseJournal Name: Frontiers in Human NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnhum.2020.602595Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnhum.2020.602595/pdfCitation Count: 3
- Potential Sex-Specific Effects of Apolipoprotein E ɛ4 on Cognitive Decline in Early Parkinson’s Disease2020RESTRICTEDTitle: Potential Sex-Specific Effects of Apolipoprotein E ɛ4 on Cognitive Decline in Early Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 2Start Page: 497End Page: 505Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.3233/jpd-202288Citation Count: 4
- Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)2020OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 5
- Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM202020OPENTitle: Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20Journal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 6Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-020-00139-6Best OA location URL: https://www.nature.com/articles/s41531-020-00139-6.pdfCitation Count: 25
- Cortical volume abnormalities in posttraumatic stress disorder: an ENIGMA-psychiatric genomics consortium PTSD workgroup mega-analysis2020OPENTitle: Cortical volume abnormalities in posttraumatic stress disorder: an ENIGMA-psychiatric genomics consortium PTSD workgroup mega-analysisJournal Name: Molecular PsychiatryPublisher: Springer Science and Business Media LLCVol: 26Issue #: 8Start Page: 4331End Page: 4343Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41380-020-00967-1Best OA location URL: https://pure.rug.nl/ws/files/203826418/s41380_020_00967_1.pdfCitation Count: 75
- Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's disease2020OPENTitle: Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 17Issue #: 5Start Page: 831End Page: 846Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12240Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.12240Citation Count: 16
-
OPENTitle: The Future of GDNF in Parkinson's DiseaseJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 12Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2020.593572Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2020.593572/pdfCitation Count: 41
- A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes2020RESTRICTEDTitle: A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodesJournal Name: Expert Review of NeurotherapeuticsPublisher: Informa UK LimitedVol: 21Issue #: 2Start Page: 169End Page: 177Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14737175.2020.1855145Citation Count: 9
- Developing new treatments in partnership for primary mitochondrial disease: What does industry need from academics, and what do academics need from industry?2020RESTRICTEDTitle: Developing new treatments in partnership for primary mitochondrial disease: What does industry need from academics, and what do academics need from industry?Journal Name: Journal of Inherited Metabolic DiseasePublisher: WileyVol: 44Issue #: 2Start Page: 301End Page: 311Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/jimd.12326Citation Count: 2